Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of long-term evolocumab therapy
2014-001524-30Phase 3Completed
- Sponsor
- Amgen
- Start
- Oct 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of evolocumab in hypercholesterolemia and cardiac morbidity, sponsored by Amgen. Primary endpoint: Subject incidence of adverse events. Started Oct 2014; status: completed.
02
Drugs
evolocumab
03
Conditions
hypercholesterolemiacardiac morbidity
Beyond the preview
Go deeper on 2014-001524-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001524-30.